Ranibizumab

Ranibizumab is a biologic medicine used in ophthalmology to treat selected retinal conditions that can cause visual impairment. It is a recombinant humanized monoclonal antibody fragment and belongs to the vascular endothelial growth factor (VEGF) inhibitor class. Ranibizumab binds to VEGF-A, a protein involved in the formation of abnormal blood vessels and increased vascular permeability. By inhibiting VEGF-A, it helps reduce abnormal vessel growth and fluid leakage in the retina, potentially stabilizing or improving vision. The medicine is administered by intravitreal injection, meaning it is injected into the vitreous cavity of the eye by a qualified ophthalmologist under aseptic conditions. Its clinical uses include neovascular or wet age-related macular degeneration, diabetic macular oedema, and macular oedema associated with retinal vein occlusion. Depending on the approved product information and jurisdiction, it may also be used for choroidal neovascularisation associated with pathological myopia, proliferative diabetic retinopathy, and retinopathy of prematurity. Treatment schedules vary according to the condition, visual response, retinal imaging findings, and the patient's clinical needs. Repeated injections and regular ophthalmic assessments are often necessary. Because intravitreal treatment carries risks, including intraocular inflammation, infection, and increased intraocular pressure, appropriate patient selection, sterile administration, and follow-up are essential.

Ranibizumab was developed as a targeted inhibitor of VEGF-A to reduce abnormal blood vessel formation and leakage in retinal diseases. It was derived from a humanized monoclonal antibody fragment designed for intraocular use. The US Food and Drug Administration (FDA) initially approved ranibizumab in 2006 for neovascular or wet age-related macular degeneration. The European Commission granted marketing authorization for Lucentis following the European Medicines Agency (EMA) assessment in January 2007. Subsequent clinical trials and regulatory decisions expanded its use to include diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and other retinal disorders. The MARINA and ANCHOR trials established its efficacy in wet age-related macular degeneration, while the RISE and RIDE trials evaluated its use in diabetic macular oedema. The RADIANCE and BRAVO studies provided evidence for treatment in myopic choroidal neovascularisation and retinal vein occlusion, respectively. In India, the Central Drugs Standard Control Organisation (CDSCO) has published regulatory records and recommendations concerning ranibizumab, including additional indications and product-specific approvals. Approved indications, doses, and paediatric uses vary between countries and formulations; current local prescribing information should therefore be consulted.

Ranibizumab is used to treat retinal diseases involving abnormal blood vessel growth, vascular leakage, or associated retinal damage. Established indications include neovascular or wet age-related macular degeneration, visual impairment due to diabetic macular oedema, and macular oedema secondary to branch or central retinal vein occlusion. Depending on the jurisdiction and specific product approval, it may also be indicated for visual impairment due to choroidal neovascularisation associated with pathological myopia, proliferative diabetic retinopathy, and retinopathy of prematurity in eligible preterm infants. Treatment aims to reduce retinal fluid and abnormal vascular activity and to preserve or improve visual function. Ranibizumab is generally used as an intravitreal treatment rather than as systemic monotherapy, and its dosing schedule is tailored to the underlying disease. The ophthalmologist determines whether treatment is appropriate by assessing visual acuity, retinal examination findings, optical coherence tomography, and other relevant investigations. Indications for infants and adults differ, and paediatric treatment should be undertaken by appropriately experienced specialists using the relevant approved product information.

Ranibizumab is administered by intravitreal injection by a qualified healthcare professional using strict aseptic technique. The commonly recommended adult dose for wet age-related macular degeneration is 0.5 mg per eye per treatment, generally administered monthly at the start of therapy. For diabetic macular oedema and macular oedema following retinal vein occlusion, approved adult dosing may be 0.3 mg or 0.5 mg per injection depending on the jurisdiction and product label; treatment is commonly repeated at approximately monthly intervals according to clinical response. For choroidal neovascularisation associated with pathological myopia, treatment may begin with monthly injections, with subsequent doses guided by visual and anatomical response and the applicable label. For proliferative diabetic retinopathy, the regimen should follow the locally approved prescribing information. Retinopathy of prematurity requires a separate paediatric dosing protocol and specialist administration; the recommended dose must not be inferred from adult regimens. Treatment duration is individualized and may involve repeated injections over an extended period, with intervals adjusted according to visual acuity, retinal imaging, recurrence, and treatment response. Patients require follow-up after injections to assess vision, intraocular pressure, inflammation, and possible complications. Only the ophthalmologist should determine injection timing, dose adjustments, or treatment discontinuation.

Common adverse effects of ranibizumab include eye discomfort, eye pain, increased intraocular pressure, small vitreous floaters, conjunctival haemorrhage, irritation, and temporary visual disturbances following injection. Some patients may experience blurred vision, redness, a sensation of a foreign body in the eye, or mild inflammation. The underlying retinal disease can also affect vision independently of treatment. Many injection-related symptoms are transient, but their severity and duration vary between patients. Patients should follow post-injection instructions and attend scheduled ophthalmic assessments. New or worsening symptoms should not automatically be assumed to be routine, particularly when accompanied by significant pain, redness, light sensitivity, or a sudden change in vision. Clinicians should assess persistent or troublesome symptoms and determine whether additional examination or treatment is needed.

Serious risks associated with ranibizumab include endophthalmitis, retinal detachment, retinal tear, intraocular inflammation, and a marked increase in intraocular pressure after injection. Rare cases of retinal vasculitis, with or without retinal vascular occlusion, have also been reported and may threaten vision. Intravitreal administration carries a risk of infection and must be performed using appropriate sterile technique. Treatment should generally not be administered in the presence of an active ocular or periocular infection or active intraocular inflammation, according to the applicable product information. Some patients may experience temporary or persistent deterioration in vision related to the underlying disease or a treatment complication. As VEGF inhibition may theoretically be associated with arterial thromboembolic events, relevant cardiovascular history should be considered, although the degree of systemic risk varies across studies and patient populations. Severe eye pain, increasing redness, photophobia, sudden visual loss, or new floaters after an injection require urgent ophthalmic assessment. Further injections may need to be withheld, interrupted, or discontinued if serious ocular complications develop.

Before treatment, clinicians should assess the diagnosis, visual acuity, retinal anatomy, ocular infection status, and relevant ophthalmic history. Intraocular pressure should be monitored when clinically indicated, particularly in patients with glaucoma or a history of pressure elevation after injections. Ranibizumab is administered locally into the eye, and systemic exposure is substantially lower than with systemic anti-VEGF treatment; however, systemic effects cannot be completely excluded. Caution may be appropriate in patients with a recent stroke, myocardial infarction, or other significant vascular disease, based on individual risk and the applicable prescribing information. Concurrent use of other intravitreal anti-VEGF medicines should be reviewed by the treating specialist, as combined treatment is not routinely interchangeable with an established regimen. Interactions with conventional oral medicines are generally limited because ranibizumab is a biologic administered locally, but concomitant ophthalmic treatments and other therapies should still be reviewed. Pregnancy and breastfeeding require individualized consideration because available safety data may be limited. In premature infants, the potential effects of treatment on developing organs and the need for long-term follow-up should be considered by the paediatric ophthalmology team. Patients should receive clear instructions on post-injection warning symptoms and follow-up appointments.

Confirm the retinal diagnosis, approved indication, intended eye, dose, and formulation before every injection. Review baseline visual acuity, retinal imaging, ocular infection status, relevant ophthalmic history, and intraocular pressure where appropriate. Intravitreal injections must be performed by trained personnel using strict aseptic technique, with appropriate preparation of the eye and careful handling of the single-use product. The medicine should be inspected for visible particles or discolouration, and preparation should follow the product-specific instructions. Document the eye treated, dose, batch details when required, and any immediate adverse events. Arrange follow-up according to the disease and treatment response, using visual acuity and retinal imaging to guide repeat injections. Counsel patients to seek urgent care for worsening eye pain, redness, light sensitivity, new floaters, or sudden deterioration in vision. For paediatric indications such as retinopathy of prematurity, dosing, timing, and follow-up should be managed by an experienced specialist team. Pharmacists should verify storage requirements, product integrity, formulation-specific dosing, and local approval status. Coordination between ophthalmologists, retinal imaging services, nurses, and pharmacy teams supports appropriate treatment and early recognition of complications.